clinical trial · NCT04318938
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·phase2·active not recruiting·n = 118
NSCLCBrigatinibTyrosine kinase inhibitor
brief summary
This is a prospective, randomized, open-label, multicenter phase II study investigating the advancing Brigatinib properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping
started
Mar 30, 2020
primary completion
Apr 30, 2026
completion
Apr 30, 2026
last updated
Mar 2, 2026
detailed description
The aim of this study is to compare efficacy of brigatinib and other 2nd-generation ALK tyrosin kinase inhibitor (TKI) in 1st and 2nd line treatment and to explore resistance patterns according to treatment and molecular properties of the tumors
official title
Advancing Brigatinib Properties in Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer (ALK+ NSCLC) Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol